Skip to main content

Interictal Type 1 Cannabinoid Receptor Binding is Increased in Female Migraine Patients

Buy Article:

$43.00 plus tax (Refund Policy)

Objective.— To compare binding of the type 1 cannabinoid receptor (CB1R) between migraine patients and healthy volunteers

Background.— It has been suggested that endocannabinoid deficiency may play a role in the pathophysiology of migraine. Nonetheless, biochemical studies substantiating this idea remain scarce and are faced with methodological shortcomings partly because of the difficulty to perform measurements of endocannabinoids within the central nervous system itself.

Methods.— An observational cross‐sectional study was conducted in 20 female migraine patients and 18 healthy women matched for age and body mass index. Positron emission tomography acquisition was performed 90 minutes after intravenous injection of the radioligand [18F]MK‐9470 to assess binding of [18F]MK‐9470 to CB1R.

Results.— Binding of CB1 R was globally increased in migraine patients vs healthy controls (average gray matter difference +16%; P = .009, 2‐sample 2‐sided Student's t‐test). There were no correlations between CB1R binding and any predefined migraine characteristics. Increases in CB1R binding were most pronounced in the anterior cingulate, mesial temporal, prefrontal, and superior frontal cortices.

Conclusion.— The increased interictal CB1R binding, especially in brain regions that exert top‐down influences to modulate pain, supports the idea that endocannibinoid deficiency is present in female patients suffering from episodic migraine.

(Headache 2012;52:433‐440)
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Document Type: Research Article

Affiliations: 1: From the Center for Clinical Pharmacology, University Hospital Gasthuisberg (K.U. Leuven), Leuven, Belgium (B.J. Van der Schueren and J.N. De Hoon); Division of Nuclear Medicine, University Hospital Gasthuisberg (K.U. Leuven), Leuven, Belgium (K. Van Laere and N. Gérard); Laboratory of Radiopharmaceutical Chemistry, University Hospital Gasthuisberg (K.U. Leuven), Leuven, Belgium (G. Bormans). 2: From the Center for Clinical Pharmacology, University Hospital Gasthuisberg (K.U. Leuven), Leuven, Belgium (B.J. Van der Schueren and J.N. De Hoon); Division of Nuclear Medicine, University Hospital Gasthuisberg (K.U. Leuven), Leuven, Belgium (K. Van Laere and N. Gérard); Laboratory of Radiopharmaceutical Chemistry, University Hospital Gasthuisberg (K.U. Leuven), Leuven, Belgium (G. Bormans).

Publication date: 2012-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more